Taysha Gene Therapies, Inc. reports company developments as a clinical-stage biotechnology company advancing adeno-associated virus, or AAV, gene therapies for severe monogenic diseases of the central nervous system. Its lead program, TSHA-102, is an intrathecally delivered, self-complementary AAV9 investigational gene transfer therapy in clinical evaluation for Rett syndrome.
Recurring updates cover TSHA-102 clinical and preclinical data, FDA regulatory interactions and designations, manufacturing and comparability topics, financial results, corporate updates, and employee inducement equity grants under Nasdaq listing rules. Company communications also describe the program’s MECP2 construct design, miRARE technology, and clinical trial activity in Rett syndrome.
Taysha Gene Therapies (Nasdaq: TSHA) announced its participation in the William Blair Biotech Focus Conference 2021. The event is scheduled for July 15, 2021, at 11:00 am ET, featuring a fireside chat format. Key executives, including RA Session II (President and CEO), Dr. Suyash Prasad (Chief Medical Officer), and Kamran Alam (Chief Financial Officer), will participate. A live webcast will be accessible via Taysha's website, with an archived version available for 60 days. Taysha focuses on developing gene therapies for central nervous system diseases.
Taysha Gene Therapies (Nasdaq: TSHA) announced the publication of new analyses of natural history data for TSHA-120 in giant axonal neuropathy (GAN) in the journal Brain. The study assessed 45 patients aged 3-21 with genetically confirmed GAN to explore genotype-phenotype correlations and markers of disease severity. The findings indicate a clinical difference between early-onset and late-onset GAN patients, with early-onset showing more severe progression. Taysha aims to leverage these insights to support its ongoing clinical trials and regulatory discussions for TSHA-120, expected to report data later this year.
Taysha Gene Therapies (Nasdaq: TSHA) announced its first virtual R&D day for analysts and investors on June 28-29, 2021. The event will showcase the company's progress in AAV-based gene therapies targeting monogenic CNS diseases. Key discussions will include programs like TSHA-120 for giant axonal neuropathy and TSHA-101 for GM2 gangliosidosis. Senior leaders and experts will present, with webcasts available live and archived for 60 days. Registration is open via LifeSci Events. Taysha aims to accelerate the development of curative treatments for rare CNS disorders.
Taysha Gene Therapies, Inc. (Nasdaq: TSHA) announced its participation in two upcoming virtual fireside chats at major biotechnology conferences on June 22, 2021. The first event is the LifeSci Genetics Medicine Conference at 10:00 am ET, while the second is the LSX Biotech Growth CEO Forum at 1:10 pm ET, focusing on optimizing value from discovery platforms. Key executives, including the CEO and CMO, will participate in these discussions. Webcasts will be available for 60 days on Taysha's corporate website.
Taysha Gene Therapies (Nasdaq: TSHA) announced its first annual stockholder meeting will take place on June 17, 2021, at 10 am ET via webcast. The meeting can be accessed through the company’s corporate website. Taysha focuses on developing AAV-based gene therapies for monogenic diseases affecting the central nervous system, with a commitment to translating therapies from bench to bedside. Their integrated approach aims to improve patient lives through innovative treatments.
Taysha Gene Therapies, Inc. (Nasdaq: TSHA) is participating in multiple upcoming healthcare conferences. The company will host a virtual fireside chat at:
- Jefferies Virtual Healthcare Conference on June 2, 2021, at 10:30 am ET
- Goldman Sachs 42nd Annual Global Healthcare Conference on June 10, 2021, at 5:30 pm ET
- JMP Securities Life Science Conference on June 16, 2021, at 12:30 pm ET
Featured participants include RA Session II, Dr. Suyash Prasad, and Kamran Alam. Webcasts will be available for 60 days on their corporate website.
Taysha Gene Therapies (Nasdaq: TSHA) has joined the newly formed Rare Disease Company Coalition, aimed at advocating for rare disease treatments. This coalition is composed of leading life sciences companies committed to overcoming the challenges in rare disease drug development. The coalition plans to engage with policymakers on critical healthcare policies, including prescription drug pricing. Taysha's CEO emphasized the importance of effective policies for innovative therapies, highlighting the company's commitment to improving treatment access for rare disease patients.
Taysha Gene Therapies (Nasdaq: TSHA) announced the appointment of Mary Newman as Chief Development Officer, enhancing its leadership team. Newman, with over 30 years in regulatory affairs and research within biotechnology, will manage program and portfolio operations, reporting to Chief Medical Officer Suyash Prasad. Her prior experience includes roles at Astellas Gene Therapies and BioMarin Pharmaceutical, where she contributed to significant drug approvals. CEO RA Session II emphasized Newman’s role in advancing Taysha’s ambitious pipeline for monogenic CNS disorders.
Taysha Gene Therapies (Nasdaq: TSHA) announced its participation in two virtual events: the 2021 RBC Capital Markets Global Healthcare Conference on May 19 at 3:05 PM ET and the Oppenheimer Rare & Orphan Disease Summit on May 21 at 4:35 PM ET. The discussions will involve key executives including RA Session II, Dr. Suyash Prasad, and Kamran Alam. Webcasts will be available in the Events & Media section of their corporate website for 60 days after the events.
Taysha Gene Therapies (Nasdaq: TSHA) reported Q1 2021 financial results, noting a net loss of $32 million, or $0.87 per share, compared to $5.4 million, or $0.50 per share in Q1 2020. The company acquired TSHA-120 for GAN, showing promising clinical data with 14 patients dosed. Preclinical results for TSHA-102 in Rett syndrome demonstrated a significant 56% survival extension in knockout mice. Taysha plans to advance five programs into Phase 1/2 trials by year-end and aims to submit an IND application for TSHA-102 by then. The company has $228.7 million in cash, expected to support operations into 2023.